Cercek: “The majority of patients in AZUR-1 in a global study were able to avoid all of standard of care”
From The Cancer Letter · 00:39:21
Show by The Cancer Letter
On Oct. 19, FDA granted an accelerated approval to dostarlimab-gxly (Jemperli) for the treatment of patients with previously untreated stage 2 or stage 3 rectal cancer that is mismatch repair deficient or microsatellite instability–high, as determined by an FDA-authorized test. In this episode of The Cancer Letter Podcast, Andrea Cercek, PI for AZUR-1 and section head of colorectal cancer at Memorial Sloan Kettering Cancer Center, appears as a special guest to discuss the results of the study, which was the global registrational trial that supported dostarlimab’s accelerated approval. Dostarlimab is sponsored by GlaxoSmithKline. The FDA approval could allow some patients to avoid chemotherapy, radiation, and surgery—treatments that can have devastating consequences for bowel, urinary, and sexual function, as well as fertility. For anxious patients concerned about forgoing the potentially curative standard of care treatment, Cercek offers reassurance and context.“I think the key thing here is that the patients are in follow-up,” Cercek said. “It's not that we say, ‘Okay, see you later. You're good. We don't need to see you again.’ No, it's very strict—every four months, evaluations with MRIs, with flexible sigmoidoscopies, monitoring of symptoms if any symptoms return, and that we could always intervene at that point and still offer curative treatment. “And I think we did in fact see that in the patients in AZUR-1 where they didn't have complete responses that then went on to standard of care, not just surgery, but as I mentioned, radiation or chemotherapy first because there is some ability to decide on which regimen you start with. The large majority of those patients did phenomenally well. And in fact, 93% of the entire population is disease-free. “So, that just tells you that there is this ability to actually intervene with standard of care if needed.”Stories mentioned in this podcast include: NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises New NOFO aims to shrink applications by 40% - The Cancer LetterNCAB ad hoc working group seeks to define its role as it approves eight reissue concepts “We could do a lot more than be another committee to check the RFAs before they go to the next level.” - The Cancer LetterMSK’s Andrea Cercek: Oncology faces learning curve as dostarlimab challenges dMMR rectal cancer standard of careFacing stage 4 cholangiocarcinoma, Keaton Herzer moved mountains to take off-label therapy, get a transplantDostarlimab becomes first FDA-approved immunotherapy for locally advanced rectal cancerKelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile A transcript of this podcast is available: https://cancerletter.com/podcastc/20261104-dostarlimab/
More episodes of The Cancer Letter
More episodes
- Brawley: ACS prostate cancer screening guideline should say no to “mass screening”
- Philadelphia cancer center directors talk city-wide collaboration: “A bench-to-bedside-to-block model”
- Brawley: ACS prostate cancer screening guideline should say no to “mass screening”
- With the U.S. measles elimination status in jeopardy, the outbreak’s epicenter sees little urgency
- Cancer breakthroughs hit the clinic, cancer policy hits the ballot box
- The Directors: VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs
- As USPSTF falters and FDA ignores clinical benefit, “the idea that screening is always good is probably gaining traction right now”
- As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”
- Anthony Letai reflects on Year One as NCI Director: “The NCI is in business”
- The Galleri MCD vote: What FDA asked its advisors to ignore
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.